The Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Impaired Glucose Tolerance

This study has been completed.
Sponsor:
Collaborator:
Lund University
Information provided by:
Skane University Hospital
ClinicalTrials.gov Identifier:
NCT01027585
First received: December 7, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted
  Purpose

To study the effect of cinnamon on postprandial blood glucose, and plasma concentrations of insulin in subjects with impaired glucose tolerance.


Condition
Diabetes

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Type 2 Diabetes or Impaired Glucose Tolerance

Resource links provided by NLM:


Further study details as provided by Skane University Hospital:

Enrollment: 10
Study Start Date: May 2009
Study Completion Date: September 2009
Detailed Description:

Ten subjects with impaired glucose tolerance were assessed in a crossover trial. A standard 75 g oral glucose tolerance test (OGTT) was served with placebo or cinnamon capsules. Finger-prick capillary and venous blood samples were taken before and 15, 30, 45, 60, 90, 120, 150, and 180 min after the start of the OGTT to measure glucose, and insulin.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All subjects were recruited from the population in southern Sweden.

Criteria

Inclusion Criteria:

  • Patients were selected for the study on the basis of the following inclusion criteria: diagnosis of impaired glucose tolerance for < 12 months before enrollment. Glucose tolerance status and fasting blood glucose levels were evaluated using the criteria established by the American Diabetes Association.

Exclusion Criteria:

  • Subjects who had thyroid disorders, or used insulin, oral hypoglycemics, and insulin-sensitizing drugs within 60 days before enrollment were excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01027585

Sponsors and Collaborators
Skane University Hospital
Lund University
Investigators
Principal Investigator: Joanna Hlebowicz, MD, PhD Skane University Hospital
  More Information

No publications provided

Responsible Party: Lars Stavenow, Departments of Medicine, Malmö University Hospital
ClinicalTrials.gov Identifier: NCT01027585     History of Changes
Other Study ID Numbers: 353/2008a
Study First Received: December 7, 2009
Last Updated: December 7, 2009
Health Authority: Sweden: Regional Ethical Review Board

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperglycemia

ClinicalTrials.gov processed this record on July 22, 2014